PTC Therapeutics, Inc

(NASDAQ:PTCT)

$35.27

Created with Raphaël 2.1.274-100100
STRONG BUY

Latest On PTC Therapeutics, Inc (PTCT):

About PTC Therapeutics, Inc (PTCT):

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is read more... also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

See Advanced Chart

General

  • Name PTC Therapeutics, Inc
  • Symbol PTCT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 959
  • Fiscal Year EndDecember
  • IPO Date2013-06-20
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.ptcbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 10.14
  • Price/Book (Most Recent Quarter) 8.53
  • Enterprise Value Revenue 9
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$6.25
  • Next Year EPS Estimate -$3.56
  • Next Quarter EPS Estimate -$1.32
  • Profit Margin -115%
  • Operating Margin -90%
  • Return on Assets -11%
  • Return on Equity -81%
  • Revenue 380.77 million
  • Earnings Per Share -$4.10
  • Revenue Per Share $5.77
  • Gross Profit -62219000
  • Quarterly Earnings Growth 23.2%
View More

Highlights

  • Market Capitalization 3.91 billion
  • EBITDA -125162000
  • PE Ratio -5.67
  • PEG Ratio 0.81
  • Analyst Target Price $61.3
  • Book Value Per Share $6.91
View More

Share Statistics

  • Shares Outstanding 70.32 million
  • Shares Float 63.7 million
  • % Held by Insiders 291%
  • % Held by Institutions 106.46%
  • Shares Short 4.77 million
  • Shares Short Prior Month 4.01 million
  • Short Ratio 8.11
  • Short % of Float 7%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 0.99
  • 52 Week High $70.82
  • 52 Week Low $37.21
  • 50 Day Moving Average 58.99
  • 200 Day Moving Average 57.85
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

PTC Therapeutics, Inc (PTCT) Dividend Calendar:

PTC Therapeutics, Inc (PTCT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


PTC Therapeutics, Inc (PTCT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

PTC Therapeutics, Inc (PTCT) Chart:

PTC Therapeutics, Inc (PTCT) News:

Below you will find a list of latest news for PTC Therapeutics, Inc (PTCT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

PTC Therapeutics, Inc (PTCT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Latest PTCT Trades:

PTC Therapeutics, Inc (PTCT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

PTC Therapeutics, Inc (PTCT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of PTC Therapeutics, Inc (PTCT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 291%
Institutional Ownership: 10646%